Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Since then, Miranda’s health insurance coverage approved a kidney transplant procedure, so the next step now is more testing ...

Discover recent advancements in near-infrared fluorescence imaging that have revolutionised lymph node tracing in cancers ...

Climate change is increasing the risk of urological diseases, including cancer and kidney conditions, while urological ...

According to the National Cancer Institute, approximately 40.5% of Americans will be diagnosed with cancer at some point ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Anktiva's pivotal trial in bladder cancer already included a cohort of patients with papillary disease, showing favorable disease-free survival rates. I would expect approval in this patient ...

It was used on five bladder cancer patients, and the outcomes for four of them have been more than favourable. They are now either disease-free or in remission. The fifth patient is currently only ...

ImmunityBio achieved a 55% disease-free rate at 12 months for BCG-unresponsive NMIBC and plans an sBLA submission in 2025. NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 ...

“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder ...

It found patients who received durvalumab were 32% less likely to experience disease progression, recurrence or death. Prof Catto said: "For many years survival rates for advanced bladder cancer ...